Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 7/20 | 0.53 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21868478 | 0.84 | RIPK1 (0.45) | RIPK1SLC6A9KDM4ECYP2C19HCRTR2 | |
| SCHEMBL15751660 | 0.77 | KDM4E (0.68) | RIPK1SLC6A9KDM4ECYP2C19NOTUM | |
| SCHEMBL25294414 | 0.76 | RBP4 (0.38) | RIPK1KDM4E | |
| SCHEMBL25294415 | 0.76 | RBP4 (0.38) | RIPK1KDM4E | |
| SCHEMBL31311132 | 0.76 | RIPK1 (0.42) | RIPK1SLC6A9HCRTR2HCRTR1SIGMAR1 | |
| SCHEMBL20188739 | 0.75 | KDM4E (0.58) | RIPK1SLC6A9KDM4ECYP2C19GPBAR1 | |
| SCHEMBL16872992 | 0.73 | MKNK1 (0.43) | RIPK1SLC6A9SIGMAR1 | |
| SCHEMBL16872993 | 0.73 | MKNK1 (0.43) | RIPK1SLC6A9SIGMAR1 | |
| SCHEMBL21868474 | 0.72 | KDM4E (0.60) | RIPK1KDM4ECYP2C19GPBAR1HCRTR2 | |
| SCHEMBL20565035 | 0.72 | RIPK1 (0.42) | RIPK1SLC6A9GPBAR1HCRTR2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885SLC6A9 4727/4885KDM4E 1312/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885SLC6A9 4727/4885KDM4E 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.